Northwire Canada EditionSaturday, November 7, 2026
Sign inSubscribe
Northwire
⌕
Gold 4,079.60 −0.8% Silver 51.94 −0.8% Copper 6.24 −0.5% Oil 90.83 +0.3% Palladium 1,017.10 −2.6% KRN 0.260 −7.1% GSKR 2.84 +5.6% ADE 0.125 +4.2% NRM 0.055 +0.0% BBB 0.520 −1.9% LGD 2.09 +1.9% DEC 0.110 +0.0% LCE 0.200 +0.0% NILI 0.515 −1.0% CDE 21.85 +6.7% CAN 0.045 +0.0% LORD 0.100 +0.0% HBM 29.49 +2.3% ELEF 0.265 +120.8% MUN 0.300 +0.0% SAGA 0.400 +6.7% Gold 4,079.60 −0.8% Silver 51.94 −0.8% Copper 6.24 −0.5% Oil 90.83 +0.3% Palladium 1,017.10 −2.6% KRN 0.260 −7.1% GSKR 2.84 +5.6% ADE 0.125 +4.2% NRM 0.055 +0.0% BBB 0.520 −1.9% LGD 2.09 +1.9% DEC 0.110 +0.0% LCE 0.200 +0.0% NILI 0.515 −1.0% CDE 21.85 +6.7% CAN 0.045 +0.0% LORD 0.100 +0.0% HBM 29.49 +2.3% ELEF 0.265 +120.8% MUN 0.300 +0.0% SAGA 0.400 +6.7%
Regulatory

Zentek Accepting Canadian Commercial Orders for ZenGUARD(TM) Enhanced Air Filters Following Health Canada Regulatory Classification

Regulatory Clearance Unlocks ZenGUARD Sales, But Nasdaq Compliance Looms

By The Northwire Desk — AI Analysis May 06, 2026 · 12:01 ZEN · 0.69 Zentek Ltd.
Executive Summary
  • Zentek Ltd. announced on May 6, 2026, that Health Canada's Pesticides Regulatory Directorate (PRD) has classified ZenGUARD™ Enhanced Air Filters as not subject to regulation under the Pest Control Products Act.
  • The exemption is based on a mechanical mode of action, resolving a regulatory uncertainty previously disclosed in February 2026 where the product was under evaluation as a "pest control product."
  • Following this classification, Zentek is officially accepting commercial orders in Canada across four pathways: Direct Purchase Orders, Federal Procurement (Innovative Solutions Canada), Licensing with HVAC supply chain participants, and Coated Filter Media sales.
  • The product maintains MERV 9 filtration validated under ASHRAE 52.2 with pressure drop equivalent to uncoated filters.
  • Intellectual Property is protected by an issued Canadian patent extending to 2041.
Material Impact
  • Regulatory Risk Removal: This news removes a specific commercialization blocker identified in the February 17, 2026 strategic update. Previously, Health Canada's classification as a "pest control product" could have delayed or complicated sales; this exemption accelerates revenue potential in the Canadian market.
  • Commercial Execution: While accepting orders is positive, it does not guarantee immediate volume or cash flow. The company must now convert these pathways into actual invoices to impact financials materially.
  • Contextual Performance: This follows a series of operational milestones (Albany Graphite PEA progress, Triera CRO launch, Litigation victory) but lacks the capital injection or strategic investment required for a "Material - Game Changer" rating.
  • Market Reaction Risk: The stock price has declined significantly from $2.38 highs to ~$0.69 lows over the past year. While this news is positive, it may be viewed as expected progress by the market given the February 2026 disclosure of ongoing regulatory engagement.
  • Nasdaq Compliance Shadow: The most critical context is the Nasdaq minimum bid price requirement ($1.00) with a deadline of August 24, 2026. Current trading levels (~$0.69) are well below this threshold. This news does not directly address the share price compliance issue, which remains a material risk to listing status.
ZEN · Price
Company Overview
  • Company: Zentek Ltd. is a diversified technology company focused on critical minerals (graphite), advanced materials (air filtration), and biotechnology (aptamers).
  • Flagship Project 1 - Albany Graphite: Located in Ontario, Canada. Aims to produce ultra-high-purity (5N+) nuclear-grade graphite using an electrothermal fluidized bed reactor (FBR) process without chlorine. Currently advancing toward a Preliminary Economic Assessment (PEA) targeted for Summer 2026.
  • Flagship Project 2 - ZenGUARD: Graphene-enhanced air filters designed to remove infectious aerosols while maintaining energy efficiency. Recently cleared by Health Canada for commercial sale in Canada.
  • Flagship Project 3 - Triera Biosciences: Subsidiary focused on aptamer-based therapeutics and diagnostics (e.g., influenza, H5N1). Generating revenue through CRO services.
Read the original news release →

More from Zentek Ltd.

Oct 26, 2026 · 06:01

Zentek withdraws from Nasdaq, rejecting share consolidation to preserve capital.

Regulatory Oct 05, 2026 · 07:25

Zentek advances nuclear graphite purification, though a massive capital expenditure gap remains unresolved for the project.

Production / Operations Oct 01, 2026 · 07:41

Zentek’s first federal order validates ZenGUARD filters, though revenue impact remains marginal.

Other Sep 24, 2026 · 07:41

Zentek filed the Albany PEA confirming a $3.85bn NPV and 27.4% IRR for its nuclear-grade graphite project.

Technical Study Sep 16, 2026 · 07:36

Zentek has been pre-qualified for Canadian defence drone coatings, although no committed orders have been secured to date.

Other Sep 14, 2026 · 07:31

Albany Graphite achieves 5N+ purity and secures its first Canadian government orders for the ZenGUARD product line.

Production / Operations